Merus (MRUS)
(Delayed Data from NSDQ)
$47.50 USD
-0.15 (-0.31%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $47.54 +0.04 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Merus N.V. [MRUS]
Reports for Purchase
Showing records 1 - 20 ( 177 total )
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Petosemtamab Powers Through Development Across 1/2/3L HNSCC; Reit. Buy and $85 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Peto Powers its Way to 1L-HNSCC with Additional ASCO Details
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Petosemtamab + Pembro Delivers Impressive 60% ORR in 1L HNSCC-And Other ASCO Hits
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Positive Ahead of Petosemtamab?s Interim Data At ASCO?24; Reit. Buy and $65 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Bullish Ahead of Petosemtamab?s Interim Data in 1L HNSCC in 2Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
MCLA-129?s Update During ESMO Asia Helps Define Pathway Forward; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for MRUS 112223
Provider: Stock Traders Daily
Analyst: Research Department
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Petosemtamab Takes Center Stage in 2024; Reit. Buy and $48 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
ESMO?23 Update Reinforces Positive INTERLINK-1 Read- Through, Coupled with Zeno Progress on All Fronts
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Petosemtamab Pivotal HNSCC Pathway Takes Shape, with Peto + Pembro Data in 1H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Peto?s The Way To Go For HNSCC; Reit. Buy and Raising Our PT to $48
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Petosemtamab Development Path Becomes Clear with Impactful Update in HNSCC During AACR ?23
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Multiple Clinical Updates in ''23 Drives A Standout BsAb Platform; Reit. Buy and Modulating PT to $40
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
The Argument of Tumor Agnostic or Tissue Specific Label for Zeno Back on the Table; Reit. Buy and Lowering Our PT to $39
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
3Q22: Feedback From the FDA on the Lead Asset. PT Reduced to $39
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Company: Merus N.V.
Industry: Medical - Biomedical and Genetics
Initial MCLA-129 Data Reports Encouraging Profile Which Should Not be Overinterpreted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A